BioWorld

June 14, 2005

View Archived Issues

Exelixis Signs Agreements Totaling More Than $100M

Read More

Renovis Halting MS Drug After Troubles In Phase Ia

Read More

Merck KGaA v. Integra: Opinion Favors Broad Patent Exemption

Read More

Other News To Note

Read More

As It Focuses On Xyotax, CTI Selling Trisenox To Cephalon

After disappointing Phase III data for the lung cancer drug Xyotax, Cell Therapeutics Inc. has sold its one marketed product - Trisenox - to Cephalon Inc. for up to $170 million. (BioWorld Today) Read More